arrow
C

Cameron D. Thomas

university of florida
H指数:15
被引数:911

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Impact of Race on Profiles of Platelet Reactivity and Clinical Outcomes in Clopidogrel-Treated Participants

氯吡格雷治疗患者中种族对血小板反应性和临床结局的影响

2025-08-280
PRE
Precision Antiplatelet Therapy after Percutaneous Coronary Intervention (Precision PCI) Registry - Informing optimal antiplatelet strategies
2024-08-160
OAAI
Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy
2024-07-0111
OAAI
CYP2C19 Genotype Is Associated With Adverse Cardiovascular Outcomes in Black Patients Treated With Clopidogrel Undergoing Percutaneous Coronary Intervention

CYP2C19基因型与接受氯吡格雷治疗的黑人患者经皮冠状动脉介入治疗的不良心血管结局相关

2024-06-183
OAAI
Evaluation of Potential Racial Disparities in CYP2C19-Guided P2Y12 Inhibitor Prescribing After Percutaneous Coronary Intervention
2022-11-196
OA
Implementing a pragmatic clinical trial to tailor opioids for acute pain on behalf of the IGNITE ADOPT PGx investigators

代表IGNITE采用PGx研究人员进行务实的临床试验,以定制用于急性疼痛的阿片类药物

2022-08-0412
OAAI
Impact of the ABCD-GENE Score on Clopidogrel Clinical Effectiveness after PCI: A Multi-Site, Real-World Investigation
2022-05-0217
OA
Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across CYP2D6 Genotype-Derived Activity Scores
2020-11-0317
OAAI
Impact of theCYP2C19*17Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention
2020-10-0236
OAAI
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline forCYP2C19and Proton Pump Inhibitor Dosing
2020-09-20188
OAAI